FindTrial
Sign In

Mycophenolate Mofetil for Immunosuppressive Therapy in Kidney Transplant Recipients: a Cohort Study of Efficacy and Safety Analysis

Mycophenolate Mofetil for Immunosuppressive Therapy in Kidney Transplant Recipients: a Cohort Study of Efficacy and Safety Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017951
Enrollment
Unknown
Registered
2018-08-24
Start date
2018-10-01
Completion date
Unknown
Last updated
2018-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplant Recipients

Interventions

Group 1:Mycophenolate Mofetil Dispersible Tablets
Group 2:Mycophenolate Mofetil Capsules

Sponsors

Department of Pharmacy, West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Allograft kidney transplant recipients; 2. Aged =18 years old; 3. Fully match with the criteria for kidney transplantation; 4. Immunosuppressive therapy including mycophenolate mofetil, tacrolimus and prednison.

Exclusion criteria

Exclusion criteria: 1. ABO-incompatible transplantation; 2. muti-organ transplantation; 3. a history of organ transplantation; 4. No response for followed up 3 times consecutively.

Design outcomes

Primary

MeasureTime frame
Recipient mortality;incidence of graft loss;incidence of acute rejection;—

Secondary

MeasureTime frame
incidence of delayed graft function;graft function;complications;—

Countries

China

Contacts

Public ContactWu Bin

Department of Pharmacy, West China Hospital, Sichuan University

binw83@qq.com+86 17716158324

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026